Antibiotics in the clinical pipeline at the end of 2015

Butler, Mark S., Blaskovich, Mark A. T. and Cooper, Matthew A. (2016) Antibiotics in the clinical pipeline at the end of 2015. The Journal of Antibiotics, 70 1: 1-22. doi:10.1038/ja.2016.72

Author Butler, Mark S.
Blaskovich, Mark A. T.
Cooper, Matthew A.
Title Antibiotics in the clinical pipeline at the end of 2015
Journal name The Journal of Antibiotics   Check publisher's open access policy
ISSN 0021-8820
Publication date 2016-06-29
Year available 2017
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1038/ja.2016.72
Open Access Status Not yet assessed
Volume 70
Issue 1
Start page 1
End page 22
Total pages 22
Place of publication London, United Kingdom
Publisher Nature Publishing Group
Language eng
Subject 3004 Pharmacology
3002 Drug Discovery
Abstract There is growing global recognition that the continued emergence of multidrug-resistant bacteria poses a serious threat to human health. Action plans released by the World Health Organization and governments of the UK and USA in particular recognize that discovering new antibiotics, particularly those with new modes of action, is one essential element required to avert future catastrophic pandemics. This review lists the 30 antibiotics and two β-lactamase/β-lactam combinations first launched since 2000, and analyzes in depth seven new antibiotics and two new β-lactam/β-lactamase inhibitor combinations launched since 2013. The development status, mode of action, spectra of activity and genesis (natural product, natural product-derived, synthetic or protein/mammalian peptide) of the 37 compounds and six β-lactamase/β-lactam combinations being evaluated in clinical trials between 2013 and 2015 are discussed. Compounds discontinued from clinical development since 2013 and new antibacterial pharmacophores are also reviewed.
Keyword In-Vitro Activity
Beta-Lactamase Inhibitor
Siderophore Monosulfactam Bal30072
Skin-Structure Infections
Clostridium-Difficile Infections
Acute Bacterial Skin
Fluoroketolide Solithromycin Cem-101
Resistant Staphylococcus-Aureus
Vivo Antibacterial Activity
Q-Index Code C1
Q-Index Status Provisional Code
Grant ID 066648
Institutional Status UQ
Additional Notes Published online 29 June 2016

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: HERDC Pre-Audit
Institute for Molecular Bioscience - Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 42 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 38 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 09 Sep 2016, 01:34:15 EST by Susan Allen on behalf of Institute for Molecular Bioscience